- 關於我們
- 理事長的話
理事長的話
製藥產業是生技製藥產業重要的一環，國內製藥產業多為從事學名藥的廠家。學名藥佔了健保75%的用藥量，卻只拿25%不到的藥品給付費用。沒有價廉物美的國產學名藥支持，健保藥品給付費用必然大幅膨脹，不僅可能拖垮健保，更增加全國民眾的醫療費用負擔。學名藥可說是健保幕後的無名英雄。
對能提供日常基礎用藥的學名藥產業，除了是台灣參與全球健康照護經濟競爭的策略性產業外，政府更應以國防工業看待。建立自主研發、生產製藥體系，以因應突發的災變、疫病、戰爭封鎖及禁運。儘管學名藥對健保的醫療品質及財務有重大貢獻及認知其對國防的重要性，相對於新藥，作為國人醫療照護基礎的學名藥產業政府沒有提供如生技新藥產業發展條例的優惠獎勵措施及較公平合理的藥價政策。政府對學名藥產業的輔導，應投入更多資源以優惠貸款、補助或租稅減免方式協助產業培養研發及製造人員及提升設備。更重要的是政府應作表率，以其公信力協同產業教育大眾，提供學名藥正確知識，瞭解學名藥品質，提升其形象。
最後，面對國際競爭，政府應輔導媒合不同廠家，匯聚各家產品建立較大及多樣性產品組合搶攻國際市場。或提供融資，媒合購併。培養有經濟規模及國際競爭力的學名藥公司。
學名藥協會當初成立的宗旨是希望結合產、官、學、研各界，凝聚共識，共同為學名藥產業創造新價值、新商機。我們希望政府能積極投入更多資源作研發、製造升級輔導，民眾教育、國際競合及訂定合理公正藥價政策，協助產業轉型，創造新價值、新商機。配合政府的投入，業者也應認知市場競爭的激烈及營運的艱困，更應有開闊的心胸，相互合作，上下整合，以使製藥業壯大同國際競爭。
In recent years, the Biotechnology and Pharmaceutical industry has become a strategic industry in Taiwan, with tremendous economical and innovative growth potential.
The generic pharmaceutical industry is the major supplier to over 75% of the drug volume utilized by the National Health Insurance (NHI), yet is receives only 25% of total NHI expenditure in financial compensation.
The current reimbursement design is economically unsustainable and unfavorable towards generic pharmaceutical manufacturers.With its quality and affordability, generic pharmaceuticals plays a critical role to support NHI quality of care with cost effectiveness.With a focus on efficiency, quality and affordability, generic pharmaceuticals plays a critical role in supporting NHI quality of care with economic sustainability.
Together with the NHI, the generic pharmaceutical industry is a long-standing partner in contributing to quality of care, national financial and economic viability, and national security and defense. The importance of a self-sufficient, local pharmaceutical manufacturing industry is particularly evident when the country faces endemic and epidemics, disasters, blockades or embargos during times of war.
The objective of TGPA is to facilitate industry, government, academia and research institution to work together to create value and opportunity for generic pharmaceuticals.
We urge our government to invest more resources to aid our manufacturers to continuously improve research, development, and production processes.We urge our government to educate our public on the high safety and quality of generic drugs. We urge our government to facilitate partnering to meet international competition and promulgate a fair NHI drug pricing system to create sustainable value and opportunity for the industry in future.
For now, we encourage stakeholders of the industry to be open minded and receptive to collaboration and integration, and to make the industry more competitive in the global area.